🔬Deep Research

AEMD — Aethlon Medical Inc · catalysts, narrative & risks

·18 sourcesAEMD forecast →

Overview

Aethlon Medical, Inc. (Nasdaq: AEMD) is a San Diego–based, clinical-stage medical device company centered on the Hemopurifier, an investigational extracorporeal device designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation [2]. As of the Oct 2, 2026 close, the stock traded around $6.45 on a tiny market capitalization (roughly $4.5–4.8M) [11][12][13]. The single most important recent development is an announced all-stock merger with North Immunology that will, upon closing, change the company's identity and ticker.

Key Recent Catalysts (last ~1–3 months)


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →